Vanguard Fiduciary Trust
ATOS icon

Vanguard Fiduciary Trust’s Atossa Therapeutics ATOS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
52,583
+348
+0.7% +$1.59K ﹤0.01% 3736
2026
Q1 		$275K Buy
+52,235
New +$331K ﹤0.01% 3410

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust's ATOS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Atossa Therapeutics (ATOS) stake by 0.67% in Q2 2026, buying an estimated $1.59K and bringing the position to 52,583 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #3736.

Vanguard Fiduciary Trust first reported a position in ATOS in Q1 2026 and has held it in 2 quarters since. The position peaked at $275K in Q1 2026. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Vanguard Fiduciary Trust held 52,583 shares of Atossa Therapeutics worth $101K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 348 Atossa Therapeutics shares in Q2 2026, an estimated $1.59K.
  • Atossa Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3736 holding.
  • Vanguard Fiduciary Trust first reported a position in Atossa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Atossa Therapeutics position peaked at $275K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.